Logo Logo
Hilfe
Hilfe
Switch Language to English

Wehlte, Lukas ORCID logoORCID: https://orcid.org/0009-0001-2436-8630; Walter, Julia ORCID logoORCID: https://orcid.org/0000-0003-4304-6159; Daisenberger, Lea; Kuhnle, Felix; Ingenerf, Maria Katharina ORCID logoORCID: https://orcid.org/0000-0001-6465-4597; Schmid-Tannwald, Christine; Brendel, Matthias ORCID logoORCID: https://orcid.org/0000-0002-9247-2843; Kauffmann-Guerrero, Diego ORCID logoORCID: https://orcid.org/0000-0003-1471-3290; Heinzerling, Lucie ORCID logoORCID: https://orcid.org/0000-0001-5718-3643; Tufman, Amanda; Pfluger, Thomas und Völter, Friederike ORCID logoORCID: https://orcid.org/0000-0001-6157-0363 (2024): The Association between the Body Mass Index, Chronic Obstructive Pulmonary Disease and SUV of the Non-Tumorous Lung in the Pretreatment [18F]FDG-PET/CT of Patients with Lung Cancer. In: Diagnostics, Bd. 14, Nr. 11, 1139 [PDF, 3MB]

Abstract

Background: A debate persists on the prognostic value of the pre-therapeutic standardized uptake value (SUV) of non-tumorous lung tissue for the risk assessment of therapy-related pneumonitis, with most studies lacking significant correlation. However, the influence of patient comorbidities on the pre-therapeutic lung SUV has not yet been systematically evaluated. Thus, we aimed to elucidate the association between comorbidities, biological variables and lung SUVs in pre-therapeutic [18F]FDG-PET/CT. Methods: In this retrospective study, the pre-therapeutic SUV in [18F]FDG-PET/CT was measured in non-tumorous areas of both lobes of the lung. SUVMEAN, SUVMAX and SUV95 were compared to a multitude of patient characteristics and comorbidities with Spearman’s correlation analysis, followed by a Bonferroni correction and multilinear regression. Results: In total, 240 patients with lung cancer were analyzed. An elevated BMI was significantly associated with increased SUVMAX (β = 0.037, p < 0.001), SUVMEAN (β = 0.017, p < 0.001) and SUV95 (β = 0.028, p < 0.001). Patients with chronic obstructive pulmonary disease (COPD) showed a significantly decreased SUVMAX (β = −0.156, p = 0.001), SUVMEAN (β = −0.107, p < 0.001) and SUV95 (β = −0.134, p < 0.001). Multiple other comorbidities did not show a significant correlation with the SUV of the non-tumorous lung. Conclusions: Failure to consider the influence of BMI and COPD on the pre-therapeutic SUV measurements may lead to an erroneous interpretation of the pre-therapeutic SUV and subsequent treatment decisions in patients with lung cancer.

Dokument bearbeiten Dokument bearbeiten